KRYS insider trading
NasdaqGS HealthcareKrystal Biotech, Inc.: insider trade history from SEC Form 4 filings.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Company website: www.krystalbio.com
KRYS insider activity at a glance
FilingIQ tracks 698 insider transactions for KRYS in filings since Sep 25, 2017. The most recent transaction is dated Sep 4, 2026.
Across the full history, 11 open-market purchases
and 559 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KRYS insider trades is 61.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KRYS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for KRYS?
- FilingIQ tracks 698 Form 4 insider transactions for KRYS (Krystal Biotech, Inc.), covering filings from Sep 25, 2017 onwards. 35 of those are dated within the last 90 days.
- Are KRYS insiders net buyers or net sellers?
- Across the full Form 4 history for KRYS, 11 transactions (2%) were open-market purchases and 559 (80%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KRYS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is KRYS in?
- Krystal Biotech, Inc. (KRYS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.69B.
Methodology & sources
Every KRYS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.